Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

Posted: May 27, 2024 at 2:47 am

FLORHAM PARK, N.J., May 24, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today that on May 21, 2024, the Company received notification from the Listing Qualifications department of the Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company has not yet filed its Form 10-Q for the quarter ended March 31, 2024 (“Q1 2024 Form 10-Q”), and because the Company remains delinquent in filing its Annual Report on Form 10-K for the year ended December 31, 2023 (“2023 Form 10-K”), does not comply with the Nasdaq continued listing requirements which require listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission. Nasdaq’s notice has no immediate effect on the listing of Celularity’s common stock and warrants, which continue to trade on the Nasdaq Capital Market under the symbols “CELU” and “CELUW”, respectively.

Read the original post:
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

Related Posts